Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, between the ages of 18 and 70 years of age, inclusive, at the time of randomization;~* Diagnosis of discoid lupus erythematosus (DLE) with or without SLE;~* Intolerance of anti-malarial therapy or ≥ 3 months of anti-malarial therapy with residual disease activity. The total CLASI activity must be ≥ 10;~* Stable dose of topical steroids no stronger than medium-potency (Class III or less) for ≥ 2 weeks and/or systemic immunosuppressive therapy at stable dose for ≥ 8 weeks prior to randomization (except for leflunomide which requires ≥ 12 weeks) are permitted;~* Oral prednisone ≤ 20 mg/day (or equivalent) is permitted; one increase or one decrease of ≤ 5 mg/day prednisone equivalent (not to exceed 20 mg/day) will be allowed within 30 days before randomization;~Exclusion Criteria:~* Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of DLE or SLE) that would, by its progressive nature and/or severity, interfere with the study evaluation, completion and/or procedures per the investigator's discretion;~* History of malignancy;~* Signs or symptoms or relevant history of a viral, bacterial, fungal, and parasitic infection, or recent history of repeated infections;~* Subjects with evidence of past or active tuberculosis~* Positive serology for HIV antibodies, hepatitis B surface antigen or hepatitis C antibodies (confirmed by PCR or RIBA) during the screening period;~* Receipt of a live vaccine within 3 months of study randomization and during the study;~* Prior use of the following agents:~* Administration of an investigational biologic agent that primarily targets the immune system -~* Rituximab, Lymphostat-B, or TACl-Ig within 9 months prior to randomization (or comparable B cell depleting or B cell inhibiting biologics); Rituximab (or other depleting CD20 targeted agents) treated patients must demonstrate a return of CD19+ B cells to \> 5/μL;~* CTLA4-Ig within 3 months prior to randomization;~* Other agents within 5 half-lives prior to randomization;~* Administration of cyclosporine, tacrolimus, sirolimus, IV immunoglobulin, and/or plasmapheresis within 3 months of randomization;~* Administration of thalidomide or lenalidomide within 3 months of randomization;~* Administration of oral or IV cyclophosphamide (or any other alkylating agent) within 9 months of randomization;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- AMG811 (Type: ACTIVE_COMPARATOR): All will receive AMG 811, either on Day 1 or Day 85
- AMG811 Placebo (Type: PLACEBO_COMPARATOR): All will receive placebo, either on Day 1 or Day 85

Based on this trial design, predict the completion outcome and termination type (if applicable).